

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/TCF4DFC28ABEN.html>

Date: November 2018

Pages: 143

Price: US\$ 3,500.00 (Single User License)

ID: TCF4DFC28ABEN

Abstracts

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018

SUMMARY

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 1, 7 and 3 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology,

Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Alopecia, Atopic Dermatitis (Atopic Eczema), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Leukemias, Myeloproliferative Disorders, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine

Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies
Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celgene Corp

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Incyte Corp

Japan Tobacco Inc

NMS Group SpA

Novartis AG

NS Pharma Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

Tragara Pharmaceuticals Inc

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles

APL-581 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHZ-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-407105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

jaktinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-317461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting

Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 01, 2018: CTI BioPharma announces the continuation of PAC203 Study following interim data review

Sep 28, 2018: Concert revises Phase IIa trial design to add new CTP-543 dose

Sep 13, 2018: Incyte announces positive data from phase 2b trial of Ruxolitinib cream in patients with atopic dermatitis

Sep 10, 2018: Lilly to Showcase Olumiant new data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, furthering innovation for patients with complex dermatological conditions

Jul 19, 2018: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)

Jul 18, 2018: CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

Jul 02, 2018: CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

Jun 21, 2018: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi) in Steroid-Refractory Acute Graft-Versus-Host Disease

Jun 21, 2018: Incyte to Present Data on Jakafi at 2018 Investor and Analyst Event

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by CJ HealthCare Corp, H2 2018
Pipeline by Concert Pharmaceuticals Inc, H2 2018
Pipeline by CTI BioPharma Corp, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by NMS Group SpA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by NS Pharma Inc, H2 2018
Pipeline by Simcere Pharmaceutical Group, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Pipeline by Tragara Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018

Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

COMPANIES MENTIONED

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celgene Corp

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Incyte Corp

Japan Tobacco Inc

NMS Group SpA

Novartis AG

NS Pharma Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

Tragara Pharmaceuticals Inc

I would like to order

Product name: Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/TCF4DFC28ABEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TCF4DFC28ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

